{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:38:13Z","timestamp":1787773093509,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To identify optical coherence tomography and optical coherence tomography angiography (OCTA) biomarkers associated with persistent retinal fluid in treatment-na\u00efve neovascular age-related macular degeneration after three loading doses of anti\u2013vascular endothelial growth factor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this retrospective study, 60 patients with treatment-na\u00efve typical neovascular age-related macular degeneration received three monthly intravitreal bevacizumab injections. Four weeks after the third injection, patients were categorized as responders (Group 1, n = 30) if no fluid was seen, or as suboptimal responders (Group 2, n = 30) if fluid persisted. Baseline optical coherence tomography and OCTA parameters were assessed, including central macular thickness, subfoveal choroidal thickness, pigment epithelial detachment height, hyperreflective foci, subretinal hyperreflective material, and macular neovascularization morphology. Optical coherence tomography angiography features were analyzed for loop morphology, branching vessels, peripheral arcades, sea fan pattern, and hypointense halo. Vessel density was quantified in the superficial capillary plexus, deep capillary plexus, and choriocapillaris.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      No significant differences were found between groups in baseline optical coherence tomography parameters (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05). Vessel density in the superficial capillary plexus, deep capillary plexus, and choriocapillaris did not differ between groups. However, OCTA revealed that loop morphology (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001), peripheral arcade (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009), and branching vessels (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.032) were more frequent in suboptimal responders. On multivariate regression, only loop morphology remained a significant independent predictor of persistent fluid (OR = 4.36,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.036).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Loop-shaped neovascular morphology on baseline OCTA independently predicted poor anatomical response to anti\u2013vascular endothelial growth factor therapy. Identifying such features may support early risk stratification and guide personalized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004702","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:00:09Z","timestamp":1760558409000},"page":"494-502","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["OPTICAL COHERENCE TOMOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY BIOMARKERS FOR PREDICTING RESPONSE TO ANTI\u2013VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4977-4942","authenticated-orcid":false,"given":"Turgay","family":"Ucak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih Kerem","family":"Dedeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Kol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyza","family":"Uysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semra Tiryaki","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260217","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R2-20260217","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"R3-20260217","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-20260217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","article-title":"A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration","volume":"50","author":"Schmidt-Erfurth","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"R5-20260217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","article-title":"Optical coherence tomography angiography","volume":"64","author":"Spaide","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R6-20260217","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials","volume":"120","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"key":"R7-20260217","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ophtha.2015.01.029","article-title":"Spectral-domain optical coherence tomography angiography of choroidal neovascularization","volume":"122","author":"de Carlo","year":"2015","journal-title":"Ophthalmology"},{"key":"R8-20260217","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/IAE.0000000000001628","article-title":"Biomarkers of neovascular activity in age-related macular degeneration using optical coherence tomography angiography","volume":"38","author":"Al-Sheikh","year":"2018","journal-title":"Retina"},{"key":"R9-20260217","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1097\/IAE.0000000000000766","article-title":"Optical coherence tomography angiography versus traditional multimodal imaging in assessing the activity of exudative age-related macular degeneration: a new diagnostic challenge","volume":"35","author":"Coscas","year":"2015","journal-title":"Retina"},{"key":"R10-20260217","doi-asserted-by":"crossref","first-page":"OCT314","DOI":"10.1167\/iovs.15-18900","article-title":"A comparison between optical coherence tomography angiography and fluorescein angiography for the imaging of type 1 neovascularization","volume":"57","author":"Inoue","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-20260217","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajo.2016.07.023","article-title":"Choriocapillaris flow features follow a power law distribution: implications for characterization and mechanisms of disease progression","volume":"170","author":"Spaide","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R12-20260217","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/IAE.0000000000003628","article-title":"Characteristics of age-related macular degeneration showing a poor response to three loading doses of anti-vascular endothelial growth factor","volume":"43","author":"Song","year":"2023","journal-title":"Retina"},{"key":"R13-20260217","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/bjophthalmol-2018-313065","article-title":"Optical coherence tomography angiography in exudative age-related macular degeneration: a predictive model for treatment decisions","volume":"103","author":"Coscas","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"R14-20260217","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10792-024-03198-3","article-title":"Predictive factors of age-related macular degeneration with poor response to three loading doses of anti-vascular endothelial growth factor","volume":"44","author":"Sariyeva Ismayilov","year":"2024","journal-title":"Int Ophthalmol"},{"key":"R15-20260217","doi-asserted-by":"crossref","first-page":"135","DOI":"10.31083\/j.fbl2704135","article-title":"Neovascular remodeling and subretinal fibrosis as biomarkers for predicting incomplete response to anti-VEGF therapy in neovascular age-related macular degeneration","volume":"27","author":"Wu","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"key":"R16-20260217","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"R17-20260217","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ajo.2014.01.019","article-title":"Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration","volume":"157","author":"Kang","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R18-20260217","doi-asserted-by":"crossref","first-page":"9994098","DOI":"10.1155\/2021\/9994098","article-title":"OCT biomarkers in neovascular age-related macular degeneration: a narrative review","volume":"2021","author":"Metrangolo","year":"2021","journal-title":"J Ophthalmol"},{"key":"R19-20260217","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/s41433-022-02360-4","article-title":"Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review","volume":"37","author":"Hanson","year":"2023","journal-title":"Eye (Lond)"},{"key":"R20-20260217","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ajo.2015.06.030","article-title":"Optical coherence tomography angiography of type 1 neovascularization in age-related macular degeneration","volume":"160","author":"Kuehlewein","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R21-20260217","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/IAE.0000000000003420","article-title":"The role of optical coherence tomography angiography in detecting and monitoring inflammatory choroidal neovascularization","volume":"42","author":"Kongwattananon","year":"2022","journal-title":"Retina"},{"key":"R22-20260217","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/s41433-022-02092-5","article-title":"Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies","volume":"37","author":"Lally","year":"2023","journal-title":"Eye (Lond)"},{"key":"R23-20260217","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"R24-20260217","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41433-025-03801-6","article-title":"Updates on novel and traditional OCT and OCTA biomarkers in nAMD","volume":"39","author":"Crincoli","year":"2025","journal-title":"Eye"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:00:34Z","timestamp":1771347634000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004702","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}